Future research will clarify if and to what extent L1CAM targeting represents a suitable strategy for innovative antitumor therapies, focusing in particular on the opportunity of defeating CSC-driven metastasis, relapse and drug resistance, thus contributing to tumor eradication. This evidence concerns the gene L1CAM and neoplasm.